MedTrace Logo

Evaluation of Exparel Adductor Canal Field Block for Pain Control After ACL Reconstruction

NCT04764916 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-02-21

No results posted yet for this study

Summary

This is a prospective, randomized study for adult patients presenting to the Carilion Clinic Institute of Orthopedics and Neurosurgery. Patients undergoing isolated ACL reconstruction will be eligible for inclusion. All patients will receive an adductor canal block (either with bupivacaine or Exparel. Patients will be given a pain diary for self-report of pill counts, pain scores, block duration, and pain control satisfaction). Pill counts and pain scores will also be taken by a team member at two and six-week post-operative visits. Primary outcomes include opioid requirements and pain scores.

Conditions

  • Anterior Cruciate Ligament Tear
  • Pain, Postoperative
  • Opioid Use

Interventions

DRUG

Liposomal bupivacaine

Liposomal bupivacaine will be used as adductor canal block

DRUG

Bupivacaine Hydrochloride

This is the facility's standard of care medication for this procedure

Sponsors & Collaborators

  • Carilion Clinic

    lead OTHER

Principal Investigators

  • Thomas K Miller, MD · Carilion Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-16
Primary Completion
2022-02-16
Completion
2022-03-02
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04764916 on ClinicalTrials.gov